The expression profile of CLEC3A, as a useful benchmark described in this study, supports the clinical utility of this biomarker in the diagnosis of metastatic SLNs in breast carcinoma, but more encouraging results merit further investigation. The gene discussed is CLEC3A; the disease is breast carcinoma.